Literature DB >> 22258274

An allosteric anti-hepsin antibody derived from a constrained phage display library.

Rajkumar Ganesan1, Yingnan Zhang, Kyle E Landgraf, S Jack Lin, Paul Moran, Daniel Kirchhofer.   

Abstract

The serine protease hepsin is highly upregulated in prostate cancer and is implicated in tumor progression. Therefore, specific inhibition of hepsin enzymatic activity by an antibody constitutes an attractive therapeutic approach. Here, we report the identification of the anti-hepsin antibody Fab25 by screening of a Fab phage display library with a restricted chemical diversity at the complementary determining regions. Hepsin with its S1 pocket occupied by 3,4-dichloro-isocoumarin was used as the 'bait' for library screening. Fab25 was highly specific and it potently inhibited hepsin activity toward a panel of synthetic and macromolecular substrates. Biochemical and enzymatic studies with synthetic substrates of variable length suggested that Fab25 acts as an allosteric inhibitor based on non-competitive inhibition kinetics. Isothermal titration calorimetric experiments showed that the high-affinity (K(D) 6.1 nM) binding of Fab25 with hepsin is enthalpically driven. Despite an unusually long CDR-H3 loop with several potential hepsin cleavage sites (Lys, Arg residues), Fab25 was not processed by hepsin. Antibody-25 should be valuable for investigating hepsin's role in cancer progression and for potential therapeutic applications. Furthermore, the herein presented phage display strategy using an active site-modified protease should be widely applicable for identifying potential allosteric anti-protease antibodies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258274     DOI: 10.1093/protein/gzr067

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  8 in total

1.  Bispecific antibodies: a novel approach for targeting prominent biomarkers.

Authors:  Akshita Gupta; Yatender Kumar
Journal:  Hum Vaccin Immunother       Date:  2020-07-02       Impact factor: 3.452

2.  Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.

Authors:  T A Tervonen; D Belitškin; S M Pant; J I Englund; E Marques; H Ala-Hongisto; L Nevalaita; H Sihto; P Heikkilä; M Leidenius; K Hewitson; M Ramachandra; A Moilanen; H Joensuu; P E Kovanen; A Poso; J Klefström
Journal:  Oncogene       Date:  2015-07-13       Impact factor: 9.867

Review 3.  Cell surface-anchored serine proteases in cancer progression and metastasis.

Authors:  Carly E Martin; Karin List
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

4.  Functional consequences of the macrophage stimulating protein 689C inflammatory bowel disease risk allele.

Authors:  Steven E Kauder; Lydia Santell; Elaine Mai; Lilyan Y Wright; Elizabeth Luis; Elsa N N'Diaye; Jeff Lutman; Navneet Ratti; Susan M Sa; Henry R Maun; Eric Stefanich; Lino C Gonzalez; Robert R Graham; Lauri Diehl; William A Faubion; Mary E Keir; Judy Young; Amitabha Chaudhuri; Robert A Lazarus; Jackson G Egen
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

5.  Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.

Authors:  Xi Tang; Sumit S Mahajan; Liem T Nguyen; François Béliveau; Richard Leduc; Julian A Simon; Valeri Vasioukhin
Journal:  Oncotarget       Date:  2014-03-15

6.  Hepsin regulates TGFβ signaling via fibronectin proteolysis.

Authors:  Topi A Tervonen; Juha Klefström; Denis Belitškin; Shishir M Pant; Pauliina Munne; Ilida Suleymanova; Kati Belitškina; Hanna-Ala Hongisto; Johanna Englund; Tiina Raatikainen; Olga Klezovitch; Valeri Vasioukhin; Shuo Li; Qingyu Wu; Outi Monni; Satu Kuure; Pirjo Laakkonen; Jeroen Pouwels
Journal:  EMBO Rep       Date:  2021-09-13       Impact factor: 8.807

7.  Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.

Authors:  Michael T Lipari; Wei Li; Paul Moran; Monica Kong-Beltran; Tao Sai; Joyce Lai; S Jack Lin; Ganesh Kolumam; Jose Zavala-Solorio; Anita Izrael-Tomasevic; David Arnott; Jianyong Wang; Andrew S Peterson; Daniel Kirchhofer
Journal:  J Biol Chem       Date:  2012-11-07       Impact factor: 5.157

8.  The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover.

Authors:  David J Wilkinson; Antoine Desilets; Hua Lin; Sarah Charlton; Maria Del Carmen Arques; Adrian Falconer; Craig Bullock; Yu-Chen Hsu; Kristian Birchall; Alastair Hawkins; Paul Thompson; William R Ferrell; John Lockhart; Robin Plevin; Yadan Zhang; Emma Blain; Shu-Wha Lin; Richard Leduc; Jennifer M Milner; Andrew D Rowan
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.